Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2911)
All Articles published online
|
Dec 21, 2011 (publication date) through Feb 18, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Gao SG, Jia RN, Feng XS, Xie XH, Shan TY, Pan LX, Song NS, Wang YF, Ding KL, Wang LD. Therapeutic effects of combined oxaliplatin and S-1 in older patients with advanced gastric cardiac adenocarcinoma. World J Gastroenterol 2011; 17(47): 5221-5226 [PMID: 22215948 DOI: 10.3748/wjg.v17.i47.5221] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v17/i47/5221.htm |
| Number | Citing Articles |
| 1 |
Mai Seki, Takaaki Sano, Masaru Ogawa, Yu Takayama, Satoshi Yokoo, Tetsunari Oyama. Relationship between histopathological therapeutic effect and prognosis in oral cancer patients after preoperative S-1 chemotherapy followed by surgery. Clinical Oral Investigations 2023; 27(8): 4817 doi: 10.1007/s00784-023-05112-0
|
| 2 |
Mitsuhiko Ota, Hiroshi Saeki, Hideo Uehara, Yoshiko Matsuda, Satoshi Tsutsumi, Tetsuya Kusumoto, Hisateru Yasui, Yasunari Ubukata, Shohei Yamaguchi, Hiroyuki Orita, Naoki Izawa, Saburo Kakizoe, Mototsugu Shimokawa, Tomoharu Yoshizumi, Yoshihiro Kakeji, Masaki Mori, Eiji Oki. Phase II clinical trial to study the safety and efficacy of combined S-1 + oxaliplatin therapy as neoadjuvant chemotherapy for locally advanced gastric cancer in older patients. International Journal of Clinical Oncology 2023; 28(9): 1166 doi: 10.1007/s10147-023-02373-3
|
| 3 |
C. de la Fouchardiere, L. Decoster, E. Samalin, C. Terret, C. Kenis, J.P. Droz, C. Coutzac, E. Smyth. Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature. Cancer Treatment Reviews 2021; 100: 102289 doi: 10.1016/j.ctrv.2021.102289
|
| 4 |
Ai Nagao, Amr S. Abu Lila, Tatsuhiro Ishida, Hiroshi Kiwada. Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: Promise for clinical application. International Journal of Pharmaceutics 2013; 441(1-2): 395 doi: 10.1016/j.ijpharm.2012.11.015
|
| 5 |
T. Wang, S.-F. Zhang, M.-Q. Qiu, Q.-L. Li. Efficacy and safety of S-1 (tegafur, gimeracil, and oteracil potassium) concurrent with 3-dimensional conformal radiotherapy for newly diagnosed squamous cell carcinoma of the lung in elderly patients. Cancer/Radiothérapie 2016; 20(3): 181 doi: 10.1016/j.canrad.2015.12.004
|
| 6 |
Ruinuo Jia, Tanyou Shan, Anping Zheng, Yaowen Zhang, Ping Lu, Guifang Zhang, Feng Wang, Zhiqiao Xu, Guobao Zheng, Dongxia Tang, Weiguo Zhang, Wanying Li, Ruonan Li, Yibo Guo, Lina Liu, Xiaoyong Luo, Yingjuan Zheng, Zhiwei Chang, Qiming Wang, Xinshuai Wang, Xiaozhi Yuan, Guoqiang Kong, Shuoguo Li, Ruina Yang, Dan Zhou, Jing Ren, Weijiao Yin, Jingxia Li, Junqian Zhang, Ziqi Wang, Manxi Sheng, Bingyi Xu, Liuyan Li, Xiaoyi Liu, Zhihao Lu, Lixin Wan, Fuyou Zhou, Shegan Gao. Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial. Journal of Clinical Oncology 2024; 42(20): 2436 doi: 10.1200/JCO.23.02009
|
| 7 |
Hai-feng Wang, Jie-qing Lv. The Clinical Evaluation of Tegafur Gimeracil Oteracil Combined with THP and DDP for Second-Line Treatment of Advanced Cardiac Carcinoma. Cell Biochemistry and Biophysics 2015; 72(3): 695 doi: 10.1007/s12013-015-0520-0
|
| 8 |
Zhan-Dong Zhang, Ye Kong, Wei Yang, Bin Zhang, Yong-Lei Zhang, Er-Min Ma, Hong-Xing Liu, Xiao-Bin Chen, Ya-Wei Hua. Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. World Journal of Surgical Oncology 2014; 12(1) doi: 10.1186/1477-7819-12-115
|